Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade
Advanced Science · 2026-07 · 13 (40)
DOI: 10.1002/advs.202521541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 02.06.2026. Verfasst von Teng Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Interferon Type I, Transcription Factors, DNA-Binding Proteins. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Innovation Action Plan, CSCO Cancer Research Fund.
Abstract (Originalsprache)
Immune checkpoint blockade (ICB) shows limited clinical activity in TNBC, largely because immune‐cold tumors fail to sustain productive innate and adaptive anti‐tumor immunity within an immunosuppressive tumor microenvironment. Here, we identify the transcription factor ARID3A as a tumor‐intrinsic regulator of this resistant state. Genetic ablation of ARID3A inflamed the tumor microenvironment, enhanced dendritic‐cell activation, increased antigen‐specific tetramer‐positive and total CD8 + T‐cell infiltration with heightened cytotoxic activity, and sensitized otherwise resistant tumors to PD‐1 blockade in vivo. Mechanistically, ARID3A restrained endogenous nucleic‐acid sensing and downstream type I interferon signaling, predominantly through cGAS‐STING with a contributory RIG‐I‐MAVS component. Through structure‐guided drug repurposing, we identified the clinically approved migraine agent rimegepant as an ARID3A‐targeting small molecule. Direct binding assays, together with binding‐pocket mutations (Y326A and R266A) in matched‐expression rescue systems, provided strong genetic evidence for on‐target engagement of rimegepant with ARID3A. Rimegepant phenocopied ARID3A loss, reactivated innate immune signaling, and markedly enhanced anti‐PD‐1 efficacy in murine TNBC models and patient‐derived organoids. Collectively, our findings define an actionable ARID3A‐IFN axis and support clinical evaluation of rimegepant‐based immunotherapy combinations, particularly in ARID3A‐high, immune‐cold TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Unit, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
- School of Clinical Medicine, Shanghai University of Medicine & Health Sciences, Shanghai, China.
ORCID-Profile: Yifei Zhu, Jian Zhang
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Innovation Action Plan
- CSCO Cancer Research Fund
- Chinese Young Breast Experts Research project
- Beijing Science and Technology Innovation Medical Development Foundation Key Project
Zitieren
APA
Zhou, T., Zhu, Y., Zeng, C., Han, J., Huang, H., Li, D., Lin, M., Jin, Y., Guo, Q., Yan, Y., Mao, X., Zhou, Y., & Zhang, J. (2026). Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade. Advanced Science, 13(40). https://doi.org/10.1002/advs.202521541
Vancouver
Zhou T, Zhu Y, Zeng C, Han J, Huang H, Li D, et al. Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade. Advanced Science. 2026;13(40). doi:10.1002/advs.202521541
BibTeX
@article{Zhou2026,
author = {Zhou, Teng and Zhu, Yifei and Zeng, Cheng and Han, Jinlu and Huang, Huiying and Li, Doudou and Lin, Mingxi and Jin, Yizi and Guo, Qin and Yan, Yuxin and Mao, Xinhui and Zhou, Yifei and Zhang, Jian},
title = {Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {40},
doi = {10.1002/advs.202521541}
}
EUVIMED